

Information for Vermont Prescribers of Prescription Drugs (Short Form)

Rezdiffra™ (resmetirom)

The prices listed below are wholesale acquisition cost (“WAC”) prices plus 20% as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about the WAC prices of these products is being provided to Vermont prescribers pursuant to Vermont law, to provide information about the relative prices of marketed drugs.

Marketed product:	WAC/pack^{1,*}:
Rezdiffra 60 mg	\$3950
Rezdiffra 80 mg	\$3950
Rezdiffra 100 mg	\$3950

Prices shown are for the lowest dosage of each product. Prices for multisource products are averaged. Multiple forms of the same product (eg, tablets and capsules) are considered 1 product, and the prices are averaged. Chewable forms of the product are not included.

Madrigal Pharmaceuticals, Inc. does not set or determine the WAC prices listed on this form or as published by a third-party publisher. WAC prices published by a third-party publisher may not reflect actual prices charged by wholesalers or the average of such prices.

Data as of: 03/20/2024

*The prices listed here do not necessarily reflect price per dosage, price per course of treatment, or the cost-effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included. This list does not imply that the products are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.

FDA, US Food and Drug Administration.

Reference: 1. Rezdiffra in Merative Micromedex®. RED BOOK. [online database]. Accessed March 20, 2024. <https://www.micromedexsolutions.com>. Subscription required to view.